Search Results
Aug 25, 2026, 17:00 ET Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: HARMONi-GI1 Meets Primary Endpoint
comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.Backed
More news about: Akeso, Inc.
Aug 25, 2026, 09:15 ET /C O R R E C T I O N -- Akeso, Inc./
cadonilimab is also planned. AK157D1 is the third next-generation ADC candidate from Akeso to enter clinical development, following AK146D1 (TROP2/Nectin-4 ADC) and AK138D1 (HER3 ADC). The clearance further advances the Company's IO2.0 + ADC2.0 strategy and expands its broad innovative oncology pipeline.B7-H3
More news about: Akeso, Inc.
Aug 25, 2026, 08:44 ET Fosun Pharma Announces 2026 Interim Results
international multi-center trials across China, the US, Europe, Australia, Japan and other geographies. As a potential best-in-class pan-tumor PD-L1-targeting ADC, HLX43 has demonstrated promising preliminary clinical efficacy featuring high potency and favorable safety profiles across multiple solid tumors types
More news about: Fosun Pharma
Aug 25, 2026, 06:15 ET Innovent Announces 2026 Interim Results and Business Updates
cancers and hematological malignancies. Focusing on the next-generation "IO + ADC" innovation strategy, the Company is advancing next-generation assets including IBI363 (PD-1/IL-2α-biased), IBI343 (CLDN18.2 ADC), and IBI3003 (GPRC5D/BCMA/CD3) into late-stage clinical development, establishing
More news about: Innovent Biologics
Aug 25, 2026, 02:13 ET Keymed Biosciences anuncia los resultados del primer semestre de 2026 y novedades empresariales
ensayos de fase avanzada, y ostenta los derechos exclusivos de comercialización global (excepto en la Gran China).CMG901/AZD0901 (CLDN18.2 ADC), un estudio global de fase III para el tratamiento de primera línea del cáncer gástrico, ha incluido su primer paciente a principios del año 2026;
More news about: Keymed Biosciences
Aug 25, 2026, 02:10 ET Keymed Biosciences gibt Ergebnisse für das erste Halbjahr 2026 sowie aktuelle Geschäftsentwicklungen bekannt
durchführen wird und die exklusiven weltweiten Vermarktungsrechte (außer im Großraum China) besitzt.CMG901/AZD0901 (CLDN18.2 ADC): An der globalen Phase-III-Studie zur Erstlinienbehandlung von Magenkrebs wurde Anfang 2026 der erste Patient aufgenommen; die perioperative Studie
More news about: Keymed Biosciences
Aug 25, 2026, 02:06 ET Keymed Biosciences annonce ses résultats pour le premier semestre 2026 et fait le point sur ses activités
les droits exclusifs de commercialisation dans le monde entier (à l'exclusion de la Grande Chine).CMG901/AZD0901 (CLDN18.2 ADC) : l'essai clinique mondial de phase III pour le traitement de première intention du cancer gastrique a recruté son premier patient début 2026 ; l'étude
More news about: Keymed Biosciences
Aug 24, 2026, 20:30 ET Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs
More news about: Antengene Corporation Limited
Aug 24, 2026, 08:35 ET WuXi XDC Delivers Strong First Half 2026 Performance, with Improving Margins and Profitability Further Strengthening Global ADC/XDC CRDMO Leadership
number of customers and projects, driven by continued active development of the global ADC and broader bioconjugates market, (ii) the increasing market share through the Group's established position as a leading ADC CRDMO service provider in that market, and (iii) the steady advancement of the Group's
More news about: WuXi XDC
Aug 23, 2026, 21:00 ET Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D
Other Novel ProgramsATG-125 (B7-H3 x PD-L1 bispecific ADC): ATG-125 is an "IO + ADC" dual-function molecule targeting B7-H3 and PD-L1, integrating the direct cytotoxic activity of an ADC with the durable immune activation of IO therapies. By simultaneously blocking B7-H3-
More news about: Antengene Corporation Limited
Aug 21, 2026, 08:58 ET Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation, and Accelerating Progress Towards C-MNC
endocrine therapy; dulpatatug* (HLX22), a novel-epitope monoclonal antibody (mAb) targeting HER2; HLX87, a HER2-targeted ADC; HLX97, an oral KAT6A/B inhibitor; HLX49, a HER2 biparatopic ADC; and HLX319, the first Chinese-developed fixed-dose subcutaneous co-formulation of pertuzumab and trastuzumab—all aimed
More news about: Henlius
Aug 21, 2026, 08:37 ET 復宏漢霖2026年中期業績：盈利能力持續躍升，進入全球價值兌現期
委員會和中國藥監局批准上市，成為首個且唯一**在中、美、歐三大主流市場獲批的國產帕妥珠單抗生物類似藥，與漢曲優®組成首個中美歐獲批的國產「曲帕雙靶」方案，貫穿從新輔助、輔助到晚期一線全程治療管理。同時，公司正加速佈局包括新型內分泌療法拉索昔芬HLX78、新表位抗HER2單抗HLX22、HER2 ADC HLX87、KAT6A/B口服抑制劑HLX97、HER2雙表位ADC HLX49及首款國產帕妥珠單抗曲妥珠單抗皮下復方制劑HLX319等，致力打造全週期、多維度的完善乳腺癌治療創新矩陣。在肺癌、消化道腫瘤等實體瘤領域，多產品協同構築增長新動能。 H藥 漢斯狀®（斯魯利單抗，歐洲商品
More news about: 復宏漢霖
Aug 21, 2026, 07:45 ET AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
novel investigational asset.1 Telisotuzumab adizutecan (Temab-A), an investigational c-Met-directed ADC with a topoisomerase 1 inhibitor (Top1i) payload: Building on encouraging preliminary activity2 observed in heavily pretreated patients,
More news about: AbbVie
Aug 21, 2026, 05:20 ET Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy
multiple proprietary technology platforms, including LeadsBody (a CD3 T-cell engager platform), X-body (a 4-1BB engager platform), TOPiKinectics (an ADC platform) and ImBiTDC (a TDC platform), which serve as the cornerstone for its continued innovation and have been validated by the clinical outcomes
More news about: Nanjing Leads Biolabs Co., Ltd.
Aug 21, 2026, 05:13 ET Keymed Biosciences Announces 2026 H1 Results and Business Updates
registrational and late‑stage trials and holds exclusive global commercialization rights (ex‑Greater China).CMG901/AZD0901 (CLDN18.2 ADC), global Phase III for first‑line gastric cancer enrolled first patient in early 2026; perioperative study is in Phase II, with expansion into biliary
More news about: Keymed Biosciences
Aug 21, 2026, 03:24 ET 3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth
retinal vein occlusion. In-licensed products, including Liporaxel® Paclitaxel Oral Solution for HER2-negative breast cancer, DB-1303 (HER2 ADC) for HER2-positive breast cancer, and WS2403 (GLP-1 receptor agonist) for chronic weight management in overweight or obese adults,
More news about: 3SBio Inc.
Aug 20, 2026, 10:09 ET Keymed Biosciences Announces 2026 H1 Results and Business Updates
global commercialisation rights (excluding the Greater China region) are solely owned by Gilead.CMG901/AZD0901 (Claudin 18.2 ADC): The CLDN18.2 ADC, in collaboration with AstraZeneca, is leading the global clinical development timeline among the first tier. CMG901/AZD0901 has obtained
More news about: Keymed Biosciences
Aug 19, 2026, 18:00 ET Piramal Pharma Limited schließt die Übernahme einer Mehrheitsbeteiligung an Yapan Bio Private Limited ab
CDMO-Geschäftsbereich von PPL, tätig sein.Yapan Bio unterstützt zudem direkt ADCelerate™ – die integrierte Festpreisplattform von PPS, die die ADC-Entwicklung für Phase I von der Forschung und Entwicklung bis zur GMP-Herstellung optimiert und so einen Abschluss innerhalb von nur 12 Monaten ermöglicht.
More news about: Piramal Pharma Solutions
Aug 19, 2026, 14:56 ET Piramal Pharma Limited completa l'acquisizione di una quota di controllo di Yapan Bio Private Limited
piattaforma integrata a prezzo fisso di PPS che semplifica lo sviluppo di ADC di Fase I dalla R&S alla GMP in soli 12 mesi. Questa acquisizione migliora ulteriormente ADCelerate™ e rafforza la capacità di PPL di immettere sul mercato ADC salvavita con rapidità e costanza.
More news about: Piramal Pharma Solutions
Aug 19, 2026, 11:21 ET Piramal Pharma Limited finalise l'acquisition d'une participation majoritaire dans Yapan Bio Private Limited
mois. Cette acquisition renforce encore davantage ADCelerate™ et consolide la capacité de PPL à commercialiser rapidement et de manière constante des ADC capables de sauver des vies.« Cet investissement stratégique ne se contente pas de stimuler notre croissance à long terme ; il nous permet également
More news about: Piramal Pharma Solutions
Aug 19, 2026, 06:36 ET Piramal Pharma Limited completa la adquisición de una participación mayoritaria en Yapan Bio Private Limited
plataforma integrada de precio fijo de PPS que optimiza el desarrollo de ADC de fase I, desde I+D hasta GMP, en tan solo 12 meses. Esta adquisición mejora aún más ADCelerate™ y refuerza la capacidad de PPL para comercializar ADC que salvan vidas con rapidez y consistencia."Esta inversión estratégica
More news about: Piramal Pharma Solutions
Aug 18, 2026, 21:00 ET Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit
preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs
More news about: Antengene Corporation Limited
Aug 18, 2026, 15:44 ET Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
Solutions (PPS), the CDMO arm of PPL. Yapan Bio also directly supports ADCelerate™ — PPS's fixed-price, integrated platform that streamlines Phase I ADC development from R&D to GMP in as little as 12 months. This acquisition further enhances ADCelerate™ and reinforces PPL's ability to deliver life-saving
More news about: Piramal Pharma Solutions
Aug 18, 2026, 15:36 ET Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
Solutions (PPS), the CDMO arm of PPL. Yapan Bio also directly supports ADCelerate™ — PPS's fixed-price, integrated platform that streamlines Phase I ADC development from R&D to GMP in as little as 12 months. This acquisition further enhances ADCelerate™ and reinforces PPL's ability to deliver life-saving
More news about: Piramal Pharma Solutions
Aug 17, 2026, 09:56 ET 科倫博泰宣佈2026年中期業績
BC的2期臨床研究正在進行中。其他ADC及DC產品公司亦布局了在適應症、療效及安全性方面與已上市ADC具備差異化及互補性的產品管線，包括SKB315(CLDN18.2 ADC)、SKB410 (Nectin-4 ADC)、SKB571 (新型雙抗ADC)、SKB107(RDC)、SKB103(TAA-IO雙抗ADC)和SKB565(新型雙載荷ADC)等創新資產。非DC產品
More news about: 科倫博泰